Abstract: An optical device is provided. The optical device includes a substrate that has a top surface and a bottom surface. The optical device also includes a cover layer disposed on the substrate, and the cover layer has a top surface and a bottom surface. The top surface of the cover layer faces the bottom surface of the substrate. The optical device further includes a first meta structure disposed on the bottom surface of the substrate and a second meta structure disposed on the top surface of the cover layer. Moreover, the optical device includes a detector disposed on the bottom surface of the cover layer.

Abstract: Systems, methods, circuits, and apparatus for managing signal transfers in semiconductor devices are provided. In one aspect, an integrated circuit includes: one or more target units each configured to receive a signal and a plurality of inverting units arranged on signal paths to the one or more target units. For each of the one or more target units, one or more corresponding inverting units of the plurality of inverting units are configured to invert the signal multiple times along a corresponding signal path to the target unit to cause a signal width of the inverted signal received by the target unit to be substantially identical to a signal width of the signal.

Abstract: An optical device is provided. The optical device includes a substrate, a waveguide layer, a first input grating, a first fold grating, and an isolation layer. The waveguide layer is disposed on the substrate. The first input grating is disposed in the waveguide layer. A first incident light passes through the first input grating to form a first light. The first fold grating is disposed in the waveguide layer. The first light passes through the first fold grating to form a first diffracted light in a first direction and a second diffracted light in a second direction. The isolation layer includes a first well array and is disposed on the waveguide layer. When the first diffracted light in the first direction travels to a first top portion corresponding to the first well array of the waveguide layer, the first diffracted light further passes through the first well array.

Abstract: An optical proximity correction (OPC) device and method is provided. The OPC device includes an analysis unit, a reverse pattern addition unit, a first OPC unit, a second OPC unit and an output unit. The analysis unit is configured to analyze a defect pattern from a photomask layout. The reverse pattern addition unit is configured to provide a reverse pattern within the defect pattern. The first OPC unit is configured to perform a first OPC procedure on whole of the photomask layout. The second OPC unit is configured to perform a second OPC procedure on the defect pattern of the photomask layout to enhance an exposure tolerance window. The output unit is configured to output the photomask layout which is corrected.

Abstract: The present invention provides a method comprising (a) obtaining a single cell gene expression profile comprising gene expression measurements for a set of genes, for a plurality of cells, and a single cell protein expression profile comprising protein expression measurements for two or more proteins, for the plurality of cells; (b) using the single cell protein expression profiles and an unsupervised learning method to assign a cell type class to at least some of the plurality of cells; and(d) applying a feature selection process to the single gene expression profiles to identify genes in the single cell gene expression profiles that are predictive of the cell type classes assigned in step (b), wherein the genes identified in step (d) form a predictor set of genes for predicting the cell type of one or more cells.

Abstract: Medical device systems and methods are disclosed herein for assessing motor symptoms in Parkinson's disease patients through passively and/or actively acquired sensor data of motor behaviors and generating motor system assessments. Passive movement data and/or active motor performance data collected from Parkinson's disease patients is representative of EQ-5D-5L, PDQ-39, and/or MDS-UPDRS health status measurement data to more accurately predict quality of life, health status, and disease severity of Parkinson's disease patients. The generated motor system assessment may be used to provide neurologists and other health professionals with more accurate treatment recommendations and disease management protocols rather than using patient surveys alone.

Abstract: Aspects of the disclosure relate to mobile-optimized software tools that may be deployed and used to measure spatial working memory across diverse clinical trial populations. For example, some aspects describe computational optimization and participatory design of a novel spatial working memory task for clinical trials relating to autism spectrum disorders (ASD) or other neurological conditions (e.g., Alzheimer's disease). Software tools as described herein may be used for measuring treatment effects on spatial working memory and/or provide treatments to improve a patient's spatial working memory. Digital biomarkers may be generated for each patient based on the patient's spatial working memory.

Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) biomarkers in patients treated with Lysine Demethylase 1 (LSD 1) inhibitors and methods of determining the sensitivity of a cell to an LSD 1 inhibitor by measuring PD biomarkers.

Abstract: The present application discloses a method to predict responsiveness of a patient, with cancer, to treatment with LSD1 inhibitors, said method comprising measuring mRNA expression levels of one or more genes selected from the list of ASCL1, DDC, CEACAM6, LRRIQ4, NR0B2, GRP, CEACAM5, SOX21, OR51E2, SEC11C, BAALC, CCDC40, RAB3B, RGS17, ABCE1, ETS2, CCDC154, SPAG6, PON1, TMEM176A, C1orf127, IGF2BP2, IGFBP5, FAM84A, FOXA2, HOXA10, NCAM1, NCAM2, NEUROD1, KRT8, ENO2, AVP, OXT, SYP, CHGA, CHGB, BCL2 and MYC.

Abstract: The present invention is directed to compositions and methods for the independent and unconstrained identification of attractor metagenes as surrogates of pure biomolecular events as well as the use of such attractor metagenes in performing medical diagnosis, prognosis, and developing appropriate therapeutic regimes.

Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.

Abstract: The present invention provides compounds having estrogenic activity selected from the group consisting of RRR-?-tocopherol, hydro-Q9 chromene, coenzyme Q9, cycloartane, 1-Feruloyl glycerol, ?-tocopherol-9, and analogues thereof. The compounds of the present invention activate ER? and ER?, and express high estrogenic activity.